What question did this study set out to answer?

This research focuses on investigating the effectiveness and safety of MGT-1141, an antibody-drug conjugate targeting DLL3 in specific cancers.

Abstract 2662: MGT-1141, an antibody-drug-conjugate targeting DLL3 positive cancers

View Full Paper

Ask AI

Bookmark

Authors

Preclinical evaluations show potent anti-tumor activity of MGT-1141 in DLL3-positive cancers, indicating its potential as a treatment option.

This research focuses on investigating the effectiveness and safety of MGT-1141, an antibody-drug conjugate targeting DLL3 in specific cancers.
In vitro and in vivo studies assessed target binding, internalization, and cytotoxic effects.
Anti-tumor efficacy was evaluated using cell line-derived and patient-derived xenograft models.
Pharmacokinetic studies were conducted in cynomolgus monkeys to determine drug exposure and tolerability.
MGT-1141 showed high specificity for DLL3 without cross-reactivity to other proteins.
It exhibited strong binding and quick internalization in DLL3-positive cells.
MGT-1141 effectively inhibited tumor growth in xenograft models with a minimal effective dose of 0.5 mg/kg.
Pharmacokinetic studies showed linear exposure and a favorable half-life.

Tsai et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Preclinical evaluations show potent anti-tumor activity of MGT-1141 in DLL3-positive cancers, indicating its potential as a treatment option.

This research focuses on investigating the effectiveness and safety of MGT-1141, an antibody-drug conjugate targeting DLL3 in specific cancers.
In vitro and in vivo studies assessed target binding, internalization, and cytotoxic effects.
Anti-tumor efficacy was evaluated using cell line-derived and patient-derived xenograft models.
Pharmacokinetic studies were conducted in cynomolgus monkeys to determine drug exposure and tolerability.
MGT-1141 showed high specificity for DLL3 without cross-reactivity to other proteins.
It exhibited strong binding and quick internalization in DLL3-positive cells.
MGT-1141 effectively inhibited tumor growth in xenograft models with a minimal effective dose of 0.5 mg/kg.
Pharmacokinetic studies showed linear exposure and a favorable half-life.

Tsai et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark